Skip to main content
Midas Edge

TuHURA Biosciences, Inc./NV

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

HURA$1.51-9.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Conde nsed Consolidated Statements of Stockholders’ Equity (Deficit)

Total
Additional · Accumulated · Stockholders'
Preferred Stock · Common Stock · Paid in · Due from · Equity · Equity
Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · (Deficit)
Balances at January 1, 202480,561,229$8,05668,013,861$6,801$86,901,394$-$(88,474,997)$(1,558,746)
Retroactive application of reverse recapitalization(63,648,386)$8,857(55,846,182)$5,367$(14,224)$-$-$-
Preferred stock (Series A ratio of 1.188, Series A-1 ratio of 1.132, and Series B ratio of 1.191) converted into common stock and multiplied by exchange ratio of 0.1789
Recast balances, beginning of period (applying exchange ratio to preferred and common)16,912,843$16,91312,167,679$12,168$86,887,170$-$(88,474,997)$(1,558,746)
Stock options exercised, cashless---10(10)---
Stock compensation expense----334,604--334,604
Net loss------(4,842,142)(4,842,142)
Balances at March 31, 202416,912,84316,91312,167,679$12,178$87,221,764$-$(93,317,139)$(6,066,284)
Stock compensation expense----275,492--275,492
Fair value of warrants associated with convertible notes payable----4,097,193--4,097,193
Net loss------(5,265,235)(5,265,235)
Balances at June 30, 202416,912,84316,91312,167,679$12,178$91,594,449$-$(98,582,374)$(6,958,834)
Total
Additional · Accumulated · Stockholders'
Preferred Stock · Common Stock · Paid in · Due from · Equity · Equity
Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · (Deficit)
Balances at January 1, 2025278,530$278,53042,323,759$42,324$125,397,691$-$(111,124,569)$14,593,976
Issuance of common shares for warrants exercised--1,208,1041,2083,560,907(3,057,904)-504,211
Stock options exercised, cashless--148,533148(148)---
Stock compensation expense----1,424,736--1,424,736
Fair value of warrants associated with convertible notes payable--------
Deemed dividend on warrant modifications--------
Series A Preferred Stock cash dividend------(2,089)(2,089)
Net loss------(6,664,371)(6,664,371)
Balances at March 31, 2025278,530$278,53043,680,396$43,680$130,383,186$(3,057,904)$(117,791,029)$9,856,463
Contributed capital for warrants exercised from stockholders----58,5423,057,904-3,116,446
Issuance of common shares, net of issuance costs--3,363,0763,3638,196,116--8,199,479
Issuance of common shares for Kineta merger--2,868,1692,8686,393,149--6,396,017
Stock options exercised, cashless--2,3052(2)---
Stock compensation expense----1,407,047--1,407,047
Series A Preferred Stock cash dividend------(2,089)(2,089)
Net loss------(9,523,835)(9,523,835)
Balances at June 30, 2025278,530$278,53049,913,946$49,913$146,438,038$-$(127,316,953)$19,449,528
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.